Efficacy of Botulinum Toxin Type A Injection on Masseter Hypertrophy

Background and Objectives: Masseter hypertrophy (MH) is characterized by abnormal enlargement of the masseter muscle (MM), leading to aesthetic concerns and functional impairment. This study aimed to evaluate the clinical efficacy and safety of botulinum toxin type A (BTX-A) injections for the reduction of masseter muscle hypertrophy (MMH). Methods: A prospective clinical study was carried out in the Maxillofacial Department of Rizgary Teaching Hospital from February 2018 to August 2019 and 19 patients were included who were suffering from MH. The condition was clinically diagnosed. With the diluted BTXA (30IU in ringer lactates injected at five masseter points, 6 iu each points ), Pre-injection and post-injection performance measurements were performed at 12 weeks on a patient-self-reported scale using a visual analog scale (VAS). Results: This study's findings indicate that 12 weeks after the administration of BTX-A, there was a significant efficacy in reducing MMH, with only one patient exhibiting no change in muscle hypertrophy post-injection but after injection was reduced and one patient . exhibit herniation Conclusion: This study established that the use of BTX-A significantly decreased MMH. These results suggest that BTX-A can be utilized as a safe and risk-free method with maximum effectiveness in treating MMH.